CNPR FDA Regulations 2 — Questions and Answers
Question 1: Which FDA regulatory pathway allows a drug manufacturer to sell a generic drug after the brand-name drug's exclusivity period expires?
- NDA (New Drug Application)
- ANDA (Abbreviated New Drug Application) (Correct answer)
- BLA (Biologics License Application)
- IND (Investigational New Drug Application)
Correct answer: ANDA (Abbreviated New Drug Application)
An ANDA allows generic manufacturers to market a drug by proving bioequivalence to the reference listed drug without repeating full clinical trials.
Question 2: Under the FDA's regulations, what is the primary purpose of a Risk Evaluation and Mitigation Strategy (REMS)?
- To set drug pricing guidelines
- To ensure the benefits of a drug outweigh its serious risks (Correct answer)
- To fast-track approval of orphan drugs
- To establish post-market surveillance timelines
Correct answer: To ensure the benefits of a drug outweigh its serious risks
REMS are required when FDA determines that additional safety measures beyond labeling are necessary to ensure a drug's benefits outweigh its risks.
Question 3: The FDA's Orange Book is an official publication that lists which of the following?
- Controlled substance schedules
- Approved drug products with therapeutic equivalence evaluations (Correct answer)
- Investigational drugs currently in clinical trials
- Over-the-counter drug monographs
Correct answer: Approved drug products with therapeutic equivalence evaluations
The Orange Book (formally 'Approved Drug Products with Therapeutic Equivalence Evaluations') helps identify generic equivalents to brand-name drugs.
Question 4: What does the FDA's 'black box warning' (also called a boxed warning) signify?
- The drug is approved only for pediatric use
- The drug carries the most serious safety warnings required by the FDA (Correct answer)
- The drug is in Phase III clinical trials
- The drug has been granted orphan drug designation
Correct answer: The drug carries the most serious safety warnings required by the FDA
A boxed warning is the strongest warning the FDA requires and alerts prescribers to serious or life-threatening risks associated with a medication.
Question 5: Which federal law established the framework requiring manufacturers to prove drug safety AND efficacy before FDA approval?
- Pure Food and Drug Act of 1906
- Durham-Humphrey Amendment of 1951
- Kefauver-Harris Drug Amendment of 1962 (Correct answer)
- Prescription Drug User Fee Act of 1992
Correct answer: Kefauver-Harris Drug Amendment of 1962
The Kefauver-Harris Amendment of 1962 required drug manufacturers to prove both safety and efficacy before FDA approval, largely in response to the thalidomide tragedy.
Question 6: Under FDA regulations, which of the following is an example of permitted 'off-label' communication by pharmaceutical representatives?
- Proactively promoting a drug for unapproved indications to increase sales
- Responding to an unsolicited request from a physician with truthful, non-misleading scientific information (Correct answer)
- Distributing reprints of studies supporting off-label uses without physician request
- Marketing a drug for pediatric use when only approved for adults
Correct answer: Responding to an unsolicited request from a physician with truthful, non-misleading scientific information
FDA guidance permits sharing scientific information about unapproved uses only when responding to unsolicited inquiries from healthcare professionals.
Question 7: The Prescription Drug Marketing Act (PDMA) of 1987 was enacted primarily to prevent which of the following?
- Generic drug counterfeiting
- Diversion and counterfeiting of prescription drugs in the drug supply chain (Correct answer)
- Off-label promotion by sales representatives
- Direct-to-consumer advertising abuses
Correct answer: Diversion and counterfeiting of prescription drugs in the drug supply chain
PDMA was enacted to combat the diversion and counterfeiting of prescription drugs, ensuring the integrity of the pharmaceutical distribution chain.
CNPR FDA Regulations 2
Which FDA regulatory pathway allows a drug manufacturer to sell a generic drug after the brand-name drug's exclusivity period expires?